35 results about "Spherical nucleic acid" patented technology

Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof. The compositions of the invention are useful for activating agonists of nucleic acid interacting complexes, such as TLRs, stimulating an immune response, and treating diseases such as infectious disease, cancer, allergies, allergic diseases, and autoimmune disease

Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.

Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.

Immunoregulatory spherical nucleic acids (irSNAs) composed of a lipid containing core and an inert Nucleic non-TLR antagonistic oligonucleotide shell are provided. Acid Shell These it-SNAs are useful for modulating an immune response.

The invention relates to a method of performing in situ hybridization such as fluorescence in situ hybridization (FISH) using liposomal spherical nucleic acids (L-SNAs) nanoparticles labeled with dye molecules. The nanoparticles contain one or more nucleic acids that recognize a target of interest in a sample.

Aspects of the invention relate to topical and ocular formulations of spherical nucleic acids (SNA), as well as methods of use thereof and compositions thereof. The formulations may include an inhibitor such as an inhibitor of tumour necrosis factor alpha (TNFa), platelet-derived growth factor subunit A (PDGFA), platelet-derived growth factor subunit B (PDGFB), platelet-derived growth factor subunit C (PDGFC), platelet-derived growth factor subunit D (PDGFD), platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), platelet-derived growth factor receptor like (PDGFRL), vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor B (VEGFB), vascular endothelial growth factor C (VEGFC) vascular endothelial growth factor D (VEGFD), vascular endothelial growth factor receptor-1 (VEGFR1), vascular endothelial growth factor receptor-2 (VEGFR2), vascular endothelial growth factor receptor-3 (VEGFR3), beta-2 adrenergic receptor (ADRB2), connective tissue growth factor (CTGF), interleukin 1 beta (IL1 β), interleukin 1 receptor-1 (IL1 R1), interleukin 1 receptor-2 (IL1R2), and interleukin 1 receptor-3 (IL1R3). Aspects of the invention further relate to nanostructures comprising self-assembling therapeutic oligonucleotides, such as antisense oligonucleotides, that are linked to a molecular species, wherein the molecular species is positioned in a core of the nanostructure and the oligonucleotides extend radially from the core.

The invention relates to spherical nucleic acids for the delivery of lipid nucleic acid particles. The lipid nucleic acid particles containing one or more therapeutic agents are coated with an oligonucleotide shell to enhance delivery.

The present disclosure is directed to compositions comprising alkyne oligonucleotides, nanoconjugates prepared from the same, and methods of their use.

Aspects of the invention relate to immunostimulatory spherical nucleic acids (IS-SNA) for the treatment of a disorder, such as cancer. The IS-SNA may be administered together with a checkpoint inhibitor.

The invention discloses a spherical nucleic acid probe and a preparation method and application thereof. The spherical nucleic acid probe uses nanogold as a core of spherical nucleic acid; double-chain DNA (deoxyribonucleic acid) formed by hybridizing three chains and an adaptor are assembled to the surface of the nanogold to form an outer shell of the spherical nucleic acid probe. The spherical nucleic acid probe has the advantages that the activity of telomerase can be detected, and the DNA complex at the surface of the probe is rich in CG nucleotide and can carry an anti-drug medicine (adriamycin), so that the spherical nucleic acid probe can be used for treating the cancer cells, and can reach targeting property in the complicated biological environment by utilizing the modified adaptor at the surface of the probe; the stability is good, the biocompatibility is good, the toxic or side effect to the cells is avoided, the detection range is broad, the sensitivity is high, and the like; the detection speed is quick, and the preparation steps are simple.

Spherical nucleic acids (SNA) carrying self-aggregating oligonucleotides are described herein. Compositions of the SNA include discrete nanostructures that are not aggregated. Related methods are also described.

The invention relates to a method of synthesizing liposomes and liposomal spherical nucleic acids with hydrophobic molecules functionalized to the surface. The lipid particles contain one or more agents that elicit an immune response.

The invention discloses a gold magnetic nanoprobe based on ordered arrangement of aptamers and application of the gold magnetic nanoprobe in okadaic acid detection (OA). The gold magnetic nanoprobe is formed by combining nanogold spherical nucleic acid and nano magnetic beads, wherein nucleic acid sequences are orderly arranged on the surface of the nanogold spherical nucleic acid; the nucleic acid sequence is formed by an aptamer with an adenine base polymeric chain at the 5'end and a DNA complementary chain with a fluorescent label at the 5 'end. The surface of the gold magnetic nanoprobe is modified with high density and is loaded with orderly arranged aptamers, so that the gold magnetic nanoprobe is high in specific recognition efficiency and simple and convenient to separate a target object, and can react with okadaic acid to release a fluorescently-labeled DNA complementary chain, and laser-induced fluorescence detection is applied, so that high-sensitivity analysis of trace OA is realized.

The invention discloses a method for detecting circulating miRNA by using a DNA machine based on quantum dot micelle spherical nucleic acid. The specific implementation method comprises the followingthree parts: (1) preparing multicolor quantum dot micelle spherical nucleic acid (QM-SNA) which is loaded with a DNA enzyme sequence and a quenching agent-modified substrate sequence; (2) triggering atarget so as to achieve automatic walking of DNA enzymes along a DNA track (the substrate sequence) on the surface of QM under the assistance of metal ions; and (3) measuring fluorescence signals ofthe multicolor QM through adoption of a fluorospectro photometer after completion of walking so as to realize detection and analysis of miRNA. According to the method for detecting the circulating miRNA by using the DNA machine based on the multicolor QM-SNA, a DNA enzyme walker is used for mediating amplification of the QM fluorescence signals, so that high-sensitivity detection of the miRNA is realized; and multi-element detection of miRNA is realized through adoption of the multi-color QM-SNA, and a new method is provided for accurate detection of the circulating miRNA.

The invention provides a cystoid type spherical nucleic acid and a preparation method and application thereof. The cystoid type spherical nucleic acid adopts a PNIPAM-S-S-Py polymer to react with functionalized nucleic acid drugs to obtain a diblock compound, the technology is simple, and the technology is applicable to large-scale production. The cystoid type spherical nucleic acid is of a specific cystoid structure, is high in stability, high in uniformity, high in biocompatibility, tumor targeting and reductive sensitivity inside cells, is degradable, and can be used for efficiently delivering the nucleic acid drugs to specific target cells. The cystoid type spherical nucleic acid can be used as a drug carrier and is high in drug-carrying efficiency, nucleic acid drugs and other drugs can be delivered effectively synchronously, and the cystoid type spherical nucleic acid is of a synergy therapy effect.

The present invention relates to methods of detecting and tracking a target molecule using a nanoparticle wherein the nanoparticle comprises a polynucleotide that can specifically associate with the target molecule, and wherein the association results in a change in a detectable marker that can be measured after association with the target molecule.

The invention relates to the technical field of a biosensor, in particular to detection of uracil-DNA glycosylase based on a chemiluminescence technique for driving a strand displacement reaction based on a tee structure and driving spherical nucleases based on a DNA walker technique. In order to solve the problems of being complex to operate and low in sensitivity for a method for detecting uracil-DNA glycosylase in the prior art, the invention provides a biosensor based on two nanometer technologies of the tee structure and DNA walker, and spherical nucleases are used for catalyzing luminalto be subjected to a chemiluminescence reaction for detection. The preparation method comprises the steps of preparing nano-Au, preparing spherical nucleic acid, and forming spherical nucleases in homogeneous phase for catalyzing the chemiluminescence reaction of the luminal. The uracil-DNA glycosylase is used for performing specific recognition and excision on U alkali, so as to realize target specificity detection. Besides, the DNA walker nanometer technology is used for realizing quick and high-sensitivity detection on targets.

The invention discloses a nucleic acid delivery system based on alkylated polypeptide as well as a preparation method and application. The alkylated polypeptide comprises a cationic polypeptide fragment and a hydrophobic fragment, wherein the cationic polypeptide fragment has an alpha-spiral secondary structure; the hydrophobic fragment is a lipid part of any one of palmitic acid, lauric acid, myristic acid and stearic acid; the amino acid sequence of the cationic polypeptide fragment is as shown in SEQ ID NO. 1; and the N-end of the cationic polypeptide fragment is connected with the hydrophobic fragment. The alkylated polypeptide can form a spherical nucleic acid delivery system based on the alkylated polypeptide with a proper size and a stable structure with nucleic acid molecules in different N/P proportions in a simple mixing manner, and transmembrane delivery of the nucleic acid molecules can be realized. Compared with the existing lipidosome and polymer transfection reagent, the alkylated polypeptide provided by the invention has the advantage that the preparation process for wrapping a nucleic acid medicine is simplified, and has the advantages of low toxicity, good biocompatibility, low cost and the like.

The invention relates to FCN (Fluorescent carbon nano-particle) based visual spherical nucleic acid as well as a preparation method and an application thereof. The visual spherical nucleic acid comprises FCNs and oligonucleotide combined on the surfaces of the FCNs. The FCNs with good fluorescence characteristics are obtained with a one-step reaction method and then are combined with oligonucleotide to prepare a visual spherical nucleic acid system; according to the method, a preparation process is simplified, nucleic acid can be effectively delivered into a cell by the visual spherical nucleic acid under the condition of absence of any other transfection reagents, the intake rate and the transfection efficiency of the cell are increased, and important application value is achieved.

The invention provides novel synthetic methods for oligonucleotide polymerization reactions that separate the deprotection and cleavage step following solid-phase oligonucleotide synthesis into two separate steps, thereby providing fully protected hydrophobic oligonucleotides that can be further manipulated in organic solvents. The disclosed methods enable the synthesis of new structures, such as brush DNA and brush RNA polymers and micellar spherical nucleic acids (SNAs